VIVA BIOTECH (01873) continued its upward momentum with gains exceeding 5%. As of press time, the stock was up 4.44% to HK$2.59, with trading volume reaching HK$20.26 million.

Guangfa Securities released a research report noting that the global AI pharmaceutical sector has recently secured multiple new contracts, with major pharmaceutical companies increasingly recognizing the strategic value of AI-driven drug discovery (AIDD). Recent developments collectively indicate that AI pharmaceuticals are transitioning from the conceptual phase to substantial implementation and platform-based applications. The firm anticipates that the acceleration trend in the AIDD industry will become more pronounced by mid-next year.

Guoyuan International previously highlighted that VIVA BIOTECH began its AI pharmaceutical layout five years ago. Currently, AI-related orders account for 12% of newly signed contracts, showing an upward trend.

Huaxin Securities noted that VIVA BIOTECH's CRO business primarily serves the early stages of drug discovery, representing a crucial application scenario for AI that can enhance drug development efficiency and success rates. Consequently, the company has launched an AI-integrated drug development platform called AIDD for its clients. As of the first half of 2025, AIDD has participated in the development of 175 projects, with AI-enabled CRO business contributing 10% of total revenue.